|
aap posts first-half sales of EUR 12.7 million (+38%) and EBIT of EUR 0.8 million (-51%)
aap Implantate AG, a medical technology company listed on the Frankfurt Stock Exchange in the Prime Standard segment, achieved after consolidation with the Dutch Fame Medical Group a 38% growth in sales in the first six months of the financial year to EUR 12.7 million (previous year: EUR 9.2 million), and an operating result of EUR 0.8 million (previous year: EUR 1.7 mil-lion). This trend in results is due to a weak first quarter. However, the Q2 result already marks a return to the previous year’s high level.
| In EUR million | H1/2007 | H1/2006 | Change on year | | Sales | 12.7 | 9.2 | +38% | | EBITDA | 1.9 | 2.4 | -23% | | EBIT | 0.8 | 1.7 | -51% | | EBT | 0.7 | 1.7 | -61% | | Net period Result | 0.4 | 1.0 | -64% | | Equity (ratio) | 22.1 (38%) | 21.6 (77%) | +3% | | Balance sheet total | 59.0 | 28.0 | +111% | | Employees | 270 | 161 | +68% |
In the first half of 2007 the Group earned an EBITDA of EUR 0.8 million (previous year: EUR 1.7 million). Group EBIT was EUR 0.8 million (previous year: EUR 1.7 million), and EBT EUR 0.7 million (previous year: EUR 1.7 million). With total assets of EUR 59.0 million (previous year: EUR 28.0 million) the equity ratio is currently 38% because the capital increase has not yet been imple-mented. After the capital increase it would be 72%.
In the second quarter aap succeeded in laying the groundwork for a successful finan¬cial year. aap showed a double-digit increase in international sales in the Trauma & Joint Reconstruction segment, while in the Biomaterials segment the company signed exclusive worldwide (excluding the U.S.) sales agreements with Zimmer (new Hi-Fatigue® bone cement) and Medtronic (Nanostim® nano–based bone replacement material). These two companies are world market leaders in their fields (orthopedics and spine), and aap expects the two new partnerships to gen-erate substantial product sales in the future. aap is currently in the process of taking over an-other product in the spine segment with a view to further expanding its biological implants business.
For the full year 2007 aap anticipates sales of EUR 28 million to EUR 30 million (previous year: EUR 18.5 million) and an EBIT margin in excess of 10%. However, since business depends on product approvals and large international customers, this may be subject to fluctuations.
For further information, please contact:
aap Implantate AG | | Lorenzweg 5 | | D-12099 Berlin | | X | | Oliver Bielenstein | Nanette Hüdepohl | | Director/CFO | Investor & Public Relations | | Tel.: +49 30 750 19 - 140 | Tel.: +49 30 75019 - 133 | | Fax: +49 30 750 19 - 290 | Fax: +49 30 75019 - 290 | | X | | WKN 506660, ISIN DE0005066609 | | Prime Standard/Regulated Market | | Traded at all German Stock Exchanges |
|
Print this page
